Company profile
Zensun (Shanghai) Sci & Tech
Recombinant neuregulin biologics for heart failure
Privately held: no public share price · China
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
Recombinant human neuregulin-1 (rhNRG-1)(Neucardin) | Phase 3 | ErbB2/ErbB4 (neuregulin pathway)Protein / enzyme therapeutic | Heart Failure |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.